← All trials
NCT07297589
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2025
- Primary completion
- Jan 31, 2027
- Completion date
- Mar 31, 2027
- First posted
- Dec 22, 2025
- Last posted
- Dec 22, 2025
- Enrollment
- 136
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Instituto Mexicano del Seguro SocialLead sponsor
- Instituto Mexicano del Seguro SocialSponsor investigator
- Universidad de GuanajuatoOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.